<DOC>
	<DOCNO>NCT00538213</DOCNO>
	<brief_summary>Since influenza vaccine administer every year frequent change antigenic composition , safety immunogenicity profile GSK Biologicals ' influenza vaccine GSK576389A re-evaluated repeat vaccine administration . In study , subject previously enrol study 104887 receive dose 2007-2008 season 's formulation Fluarix GSK576389A . Only subject previously enrol study 104887 eligible participation study .</brief_summary>
	<brief_title>Evaluation Safety Immunogenicity GSK Bio 's Influenza Vaccine GSK576389A After Repeated Vaccination Elderly Adults</brief_title>
	<detailed_description>This study year 2 revaccination study . First year revaccination do study 104887 ( NCT00386698 ) . Primary study study 104886 ( NCT00318149 ) . This study involve 2 age group ( base primary study ) : Subjects enrol ≥ 65 year age group primary study . Subjects enrol 18-40 year age group primary study . The Protocol Posting update order comply FDA Amendment Act , Sep 2007</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects previously vaccinate GlaxoSmithKline Biologicals Fluarix™ GSK576389A investigational vaccine 104887 study ( NCT00386698 ) . Subjects investigator believe comply requirement protocol enrol study . A male female age 19 42 year 66 year old time vaccination . Written inform consent obtain subject . Free acute aggravation health status establish clinical evaluation enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day prior vaccination , plan use study period . Administration license vaccine within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) prior enrolment study . Planned administration vaccine foreseen study protocol 21 day vaccination . Planned administration influenza vaccine study vaccine entire study period . Vaccination influenza since January 2007 Northern Hemisphere 2007/2008 influenza vaccine 2006/2007 influenza vaccine . History confirm influenza infection since date previous vaccination . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior administration study vaccine . ( For corticosteroid , mean prednisone , equivalent , ≥0.5 mg/kg/day . Inhaled topical steroid allow . ) Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History hypersensitivity previous dose influenza vaccine . History allergy reaction likely exacerbate component vaccine ( ) Acute ( active ) clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine clinical evaluation ( medical history medical history direct physical examination ) preexist laboratory screening test . Acute disease time enrolment . ( Acute disease define presence moderate severe illness without fever . All vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e . Axillary temperature &lt; 37.5°C / Oral temperature &lt; 37.5°C ) . Administration immunoglobulins and/or blood product within three month precede first administration study vaccine plan administration study . Any medical condition intramuscular injection contraindicate . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Influenza vaccine GSK576389A</keyword>
	<keyword>Fluarix</keyword>
	<keyword>Influenza infection</keyword>
</DOC>